Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Stress Prevention and Stress Management Techniques IV01:26

Stress Prevention and Stress Management Techniques IV

Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dietary Guidelines 2025-2030 For Americans Are Concerning For Liver Health.

The American journal of gastroenterology·2026
Same author

Alcohol-Related Liver Disease: A Review.

JAMA·2026
Same author

On the Label: Implementation of Health Warnings on Alcohol Products in 13 European Countries.

Drug and alcohol review·2026
Same author

Investigating the Impact of Carboxylated Polystyrene Nanoplastics in the Liver Using Cell Lines and Precision-Cut Liver Slices.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.

Gastroenterology·2026
Same author

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

The Lancet regional health. Europe·2026

Related Experiment Video

Updated: Jun 11, 2026

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public

Elisa Pose1,2, Luis Antonio Díaz3,4, Richard Parker5

  • 1Liver Unit, Hospital Clínic of Barcelona, Fundació Clínic per a la Recerca Biomédica (FCRB) - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

The Lancet Regional Health. Europe
|June 10, 2026
PubMed
Summary
This summary is machine-generated.

Alcohol-related liver disease (ALD) is a major preventable health issue in Europe. Implementing effective alcohol policies and improving integrated care are crucial to reduce ALD burden and mortality.

Keywords:
Alcohol use disorderAlcohol-associated liver diseaseAlcohol-related liver diseaseCirrhosisEpidemiologyEthanolHigh-risk populationIndustryPolicyScreening

More Related Videos

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

Related Experiment Videos

Last Updated: Jun 11, 2026

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

Area of Science:

  • Hepatology and Public Health
  • Policy Evaluation
  • Clinical Medicine

Background:

  • Alcohol-related liver disease (ALD) is a significant cause of preventable death in Europe.
  • Implementation of effective alcohol policies is inconsistent due to industry interference and policy inertia.
  • The rising burden of ALD and metabolic-associated liver disease (MetALD) is linked to increased alcohol consumption, metabolic risk factors, and fragmented healthcare.

Purpose of the Study:

  • To examine the epidemiology, policy, and clinical evidence of ALD and MetALD in Europe.
  • To identify challenges in policy implementation and healthcare system preparedness.
  • To propose priorities for policy reform, stigma reduction, prevention, and research.

Main Methods:

  • Combines epidemiological data, policy evaluations, and clinical evidence.
  • Analyzes factors contributing to the growing burden of ALD and MetALD.
  • Reviews current screening strategies and multidisciplinary care models.

Main Results:

  • Inconsistent implementation of alcohol policies hinders harm reduction.
  • Fragmented healthcare systems and delayed diagnosis exacerbate ALD burden.
  • Increased alcohol intake and metabolic risk factors drive the rise in liver disease.

Conclusions:

  • Policy reform, stigma reduction, and youth prevention are essential.
  • Integrated multidisciplinary and digital care models show promise for managing ALD.
  • Further research into biomarkers, pharmacotherapies, and AI tools is needed.